Making Anesthesiology More Science, Less Art
Executive Summary
When it comes to monitoring patient consciousness levels during surgery, anesthesiology is as much art as science, traditionally relying on the anesthesiologist's judgment in the absence of instrumentation. The worst case result of this inexactitude, while rare, is everyone's worst nightmare, a condition called surgical awareness, where a patient is awake and can feel the pain but is paralyzed and unable to respond. The more common problem is the over-medication of patients, which results in accompanying side effects and longer recovery times. Aspect Medical has developed the first monitor to enable anesthesiologists to determine a patient's consciousness level to permit physicians to assess the amount of anesthesia necessary for sedation and track the risk of awareness. It's been a long haul for Aspect, which started in 1987 as a cardiology company and has survived a near bankruptcy and a pulled IPO along the way. But the result is the first major medical device IPO in nearly two years and a first mover advantage in a large market.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.